Robeco Institutional Asset Management B.V. Buys 160,383 Shares of AbbVie Inc. $ABBV

Robeco Institutional Asset Management B.V. lifted its stake in AbbVie Inc. (NYSE:ABBV) by 5.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,323,036 shares of the company’s stock after purchasing an additional 160,383 shares during the quarter. AbbVie comprises 1.1% of Robeco Institutional Asset Management B.V.’s portfolio, making the stock its 11th biggest holding. Robeco Institutional Asset Management B.V. owned about 0.19% of AbbVie worth $769,416,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Brighton Jones LLC boosted its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of AbbVie during the 1st quarter worth about $383,000. Ashton Thomas Private Wealth LLC boosted its stake in shares of AbbVie by 3.9% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 39,401 shares of the company’s stock worth $8,255,000 after purchasing an additional 1,479 shares during the period. Finally, CTC Alternative Strategies Ltd. bought a new position in AbbVie during the 1st quarter valued at about $968,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $220.57 on Tuesday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market capitalization of $389.83 billion, a price-to-earnings ratio of 167.10, a PEG ratio of 0.96 and a beta of 0.36. The stock has a 50 day moving average price of $226.54 and a 200 day moving average price of $214.39.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the business posted $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.